- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02926092
Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)
A Prospective, Multicenter, Longitudinal, Observational Natural History Study to Evaluate Disease Progression in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) With Misfolded Rod Opsin Mutations
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75231
- Texas Retina Associates,
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- The subject has 1 documented pre-specified heterozygous rhodopsin gene (RHO) mutation confirmed by genetic testing (mutations will include P23H, T17M, and R135W).
The subject has at least 1 eye that meets all 3 of the following criteria:
- A measurable EZ area as determined by an evaluation of EZ limits on sdOCT scan, with a horizontal EZ width of greater than 3 mm
- BCVA of greater than or equal to 35 letters as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS; equivalent to 20/200 on a Snellen chart).
- A kinetic VF of greater than 10 degrees diameter in the horizontal meridian with a spot size of III
- The subject has the ability to comply with the clinical protocol, in the opinion of the investigator.
- The subject has a clear ocular media and adequate pupillary dilation in both eyes to permit adequate visual assessments in the opinion of the investigator.
- The subject has agreed to abstain from any protocol-prohibited medication(s) during study participation.
- The subject is medically stable in the opinion of the investigator and able to fulfill the protocol requirements, including the ability to complete the assessments, without placing an undue burden on the subject/subject's family.
- The subject and/or subject's parent(s) or legally authorized guardian(s) has voluntarily signed an Institutional Review Board (IRB)/ ethics committee (EC)-approved informed consent and assent form(s), as applicable, after all relevant aspects of the study have been explained and discussed with the subject and/or the subject's parent(s) or legally authorized guardian(s).
- The subject, subject's parent(s), or legally authorized guardian(s) is able to understand the nature, scope, and possible consequences of the study and agrees to comply with the protocol-defined, scheduled assessments.
Exclusion Criteria:
- The subject is participating in an interventional clinical trial or has participated in an interventional clinical trial within 90 days of screening; participation in non-interventional observational studies is permitted.
- The subject has received treatment or has been in the treatment arm of a clinical trial for gene therapy, stem cell therapy, retinal progenitor cell therapy, tissue transplantation, device or drug delivery implantation, or other similar invasive therapy.
The subject has any of the following medical conditions that will interfere with consistent follow-up over any part of the study:
- Stroke
- Severe or unstable coronary disease
- End-stage or aggressive malignancy
- General poor health or uncontrolled or severe disease (eg, cardiovascular, neurological, psychological, pulmonary,renal, hepatic, endocrine, or gastrointestinal disorders) that in the opinion of the investigator would interfere with participation in the study
The subject has any of the following ocular conditions that could interfere with or confound follow-up of disease progression:
- Glaucoma
- Diabetic retinopathy
- Choroidal neovascularization
- Retinal inflammatory disease
- Cataract worse than grade 2 (nuclear, posterior subcapsular [PSC], or cortical)
- High myopia (≥8 diopters)
- Herpes simplex virus of the eye
- Acute infection or inflammation
- Any ocular condition that in the opinion of the investigator would interfere with the ability to assess retinal morphology and functionality
- The subject has had intraocular surgery within 90 days prior to screening.
The subject currently requires the following protocol prohibited medications or has ingested such medication within 30 days of screening:
Plaquenil Thioridazine Clofazimine Deferoxamine Phenothiazine Chlorpromazine Cisplatin Valproic acid Any other drugs with known visual side effects
- The subject has 3 first- or second-degree family members already enrolled in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Arm 1
Observation of progression of disease over time.
|
Observation of progression of disease over time
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Progression of disease over time in adRP patients with misfolded rod opsin mutations using ellipsoid zone (EZ) area measurements
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by EZ width
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by visual fields (kinetic and static)
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by dark-adapted rod visual fields
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by electroretinography (ERG): dark- and light-adapted
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by best corrected visual acuity (BCVA)
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Vision-related function and quality of life as measured by 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) plus its additional items
Tidsram: Baseline to 4 years
|
Baseline to 4 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Shire Director, Takeda
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SHP630-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Retinit Pigmentosa
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasAvslutadX-Linked Retinitis PigmentosaStorbritannien, Förenta staterna
-
Oslo University HospitalRekryteringRetinit Pigmentosa | Retinitis Pigmentosa 11Norge
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... och andra samarbetspartnersRekryteringRetinitis Pigmentosa (RP)Pakistan
-
AbbVieAktiv, inte rekryterandeAvancerad Retinitis PigmentosaFörenta staterna
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)AvslutadRetinitis Pigmentosa (RP)Förenta staterna
-
Janssen Research & Development, LLCJanssen Research & Development, LLCAktiv, inte rekryterandeX-Linked Retinitis PigmentosaBelgien, Kanada, Förenta staterna, Israel, Storbritannien, Spanien, Danmark, Frankrike, Italien, Nederländerna, Schweiz
-
Janssen Research & Development, LLCAktiv, inte rekryterandeX-Linked Retinitis PigmentosaFörenta staterna, Storbritannien
-
GenSight BiologicsRekryteringIcke-syndromisk Retinitis PigmentosaFörenta staterna, Frankrike, Storbritannien
-
Janssen Research & Development, LLCJanssen Research & Development, LLCAktiv, inte rekryterandeX-Linked Retinitis PigmentosaFörenta staterna, Kanada, Israel, Storbritannien, Spanien, Danmark, Frankrike, Belgien, Italien, Nederländerna, Schweiz
-
BiogenAvslutadX-Linked Retinitis PigmentosaFörenta staterna, Storbritannien
Kliniska prövningar på Observation
-
Masonic Cancer Center, University of MinnesotaAvslutadAkut leukemi | Kemoterapi-inducerad tarmbarriärskadaFörenta staterna
-
Centre Hospitalier Régional d'OrléansAvslutad
-
Dokuz Eylul UniversityIzmir Katip Celebi UniversityAvslutad
-
Universidad Autonoma de MadridOkänd
-
University of BergenEuropean Society of Intensive Care MedicineAvslutadKritisk sjukdom | Gammal ålder; Svaghet | ÖverlevnadNorge
-
Iain BressendorffDitte Hansen MD PhD; Casper Rydahl MD; Anders Nordholm MD PhD; Eva Gravesen...Har inte rekryterat ännuNefrotiskt syndrom | Minimal förändringssjukdom | Membranös nefropati | Primär fokal segmentell glomeruloskleros
-
MultiCare Health System Research InstituteRekrytering
-
Royal Marsden NHS Foundation TrustHar inte rekryterat ännu
-
Second Affiliated Hospital, School of Medicine,...Jinhua People's Hospital; Jinhua Municipal Central Hospital; Yiwu Central... och andra samarbetspartnersRekrytering
-
Mohamed ElsawyRekrytering